{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:04:02Z","timestamp":1790147042587,"version":"4.0.1"},"reference-count":97,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRCEP"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>The NLR family pyrin domain\u2013containing 3 (NLRP3) inflammasome is a\ncentral driver of neuroinflammation and demyelination in multiple sclerosis (MS). MCC950, a selective small-molecule NLRP3 inhibitor, has emerged as a promising therapeutic candidate for MS\nby suppressing inflammasome formation and downstream cytokine release.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science using the keywords \u201cNLRP3 inflammasome,\u201d \u201cMCC950,\u201d \u201cmultiple sclerosis,\u201d \u201cexperimental\nautoimmune encephalomyelitis,\u201d and \u201cneuroinflammation.\u201d Articles published up to 2025, including in vivo and preclinical studies, were evaluated to assess the mechanistic and therapeutic potential of MCC950 in MS<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Evidence from experimental autoimmune encephalomyelitis (EAE) and cuprizone-induced\ndemyelination models demonstrates that MCC950 suppresses NLRP3\u2013ASC\u2013caspase-1 oligomerization, reduces IL-1\u03b2\/IL-18 release, and inhibits microglial and astrocytic activation. Treatment preserves oligodendrocyte integrity, mitigates axonal loss, and maintains synaptic function. Delivery\nsystems such as PEGylated nanoparticles enhance MCC950\u2019s bioavailability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>MCC950 administration has been represented as a novel therapeutic strategy due to its\ntargeted selectivity and is currently under further discovery in various combination therapies, which\nshow synergistic efficacy with agents such as rapamycin, metformin, and Anakinra, expanding its\ntherapeutic spectrum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Altogether, MCC950 represents a potent inhibitor of NLRP3 inflammasome activity\nwith dual anti-inflammatory and neuroprotective effects in preclinical MS models. Future research\nshould focus on optimizing pharmacokinetics, clarifying off-target interactions, and validating clinical efficacy to translate these findings into patient-centered therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0127724328444835260407154423","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:47:42Z","timestamp":1778842062000},"page":"327-337","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanistic Insights and Therapeutic Potential of MCC950 as a NLRP3 Inflammasome Inhibitor in Multiple Sclerosis: A Narrative Review"],"prefix":"10.2174","volume":"21","author":[{"given":"Fatemeh","family":"Rabiei","sequence":"first","affiliation":[{"name":"Student Research Committee, Babol University of Medical Sciences, Babol, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Askari","sequence":"additional","affiliation":[{"name":"Student Research Committee, Babol University of Medical Sciences, Babol, Iran"},{"name":"Health Policy Research Center,Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshia","family":"Vala","sequence":"additional","affiliation":[{"name":"Student Research Committee, Babol University of Medical Sciences, Babol, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrnaz","family":"Mardazad","sequence":"additional","affiliation":[{"name":"Student Research Committee, Babol University of Medical Sciences, Babol, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Ghasemi-Kasman","sequence":"additional","affiliation":[{"name":"Mobility Impairment Research Center, HealthResearch Institute, Babol University of Medical Sciences, Babol, Iran"},{"name":"Department of Physiology, School of Medicine,Babol University of Medical Sciences, Babol, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/imr.12912","volume":"297","author":"Kanneganti T.D.","year":"2020","unstructured":"Kanneganti T.D.; Intracellular innate immune receptors: Life inside the cell. Immunol Rev  2020,297(1),5-12","journal-title":"Immunol Rev"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1600-065X.2012.01146.x","volume":"249","author":"Tang D.","year":"2012","unstructured":"Tang D.; Kang R.; Coyne C.B.; Zeh H.J.; Lotze M.T.; PAMPs and DAMP s: Signal 0s that spur autophagy and immunity. Immunol Rev  2012,249(1),158-75","journal-title":"Immunol Rev"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/sj.cdd.4402038","volume":"14","author":"Martinon F.","year":"2007","unstructured":"Martinon F.; Tschopp J.; Inflammatory caspases and inflammasomes: Master switches of inflammation. Cell Death Differ  2007,14(1),10-22","journal-title":"Cell Death Differ"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"8041","DOI":"10.1073\/pnas.0611496104","volume":"104","author":"Duncan J.A.","year":"2007","unstructured":"Duncan J.A.; Bergstralh D.T.; Wang Y.; Cryopyrin\/NALP3 binds ATP\/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. Proc Natl Acad Sci USA  2007,104(19),8041-6","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fimmu.2017.00036","volume":"8","author":"Pellegrini C.","year":"2017","unstructured":"Pellegrini C.; Antonioli L.; Lopez-Castejon G.; Blandizzi C.; Fornai M.; Canonical and non-canonical activation of nlrp3 inflammasome at the crossroad between immune tolerance and intestinal inflammation. Front Immunol  2017,8,36","journal-title":"Front Immunol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/bpa.12477","volume":"27","author":"Barclay W.","year":"2017","unstructured":"Barclay W.; Shinohara M.L.; Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Brain Pathol  2017,27(2),213-9","journal-title":"Brain Pathol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"E6065","DOI":"10.1073\/pnas.1722041115","volume":"115","author":"McKenzie B.A.","year":"2018","unstructured":"McKenzie B.A.; Mamik M.K.; Saito L.B.; Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis. Proc Natl Acad Sci USA  2018,115(26),E6065-74","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"974","DOI":"10.4049\/jimmunol.0904145","volume":"185","author":"Gris D.","year":"2010","unstructured":"Gris D.; Ye Z.; Iocca H.A.; NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J Immunol  2010,185(2),974-81","journal-title":"J Immunol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"ra38","DOI":"10.1126\/scisignal.2002767","volume":"5","author":"Inoue M.","year":"2012","unstructured":"Inoue M.; Williams K.L.; Oliver T.; Interferon-\u03b2 therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Sci Signal  2012,5(225),ra38","journal-title":"Sci Signal"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.4049\/jimmunol.1600035","volume":"197","author":"Primiano M.J.","year":"2016","unstructured":"Primiano M.J.; Lefker B.A.; Bowman M.R.; Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary inflammation. J Immunol  2016,197(6),2421-33","journal-title":"J Immunol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"E9371","DOI":"10.1073\/pnas.1812744115","volume":"115","author":"Green J.P.","year":"2018","unstructured":"Green J.P.; Yu S.; Mart\u00edn-S\u00e1nchez F.; Chloride regulates dynamic NLRP3-dependent ASC oligomerization and inflammasome priming. Proc Natl Acad Sci USA  2018,115(40),E9371-E9380","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1089\/ars.2019.7727","volume":"32","author":"To E.E.","year":"2020","unstructured":"To E.E.; Erlich J.R.; Liong F.; Mitochondrial reactive oxygen species contribute to pathological inflammation during influenza a virus infection in mice. Antioxid Redox Signal  2020,32(13),929-42","journal-title":"Antioxid Redox Signal"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jconrel.2017.12.015","volume":"270","author":"Zhou Y.","year":"2018","unstructured":"Zhou Y.; Peng Z.; Seven E.S.; Leblanc R.M.; Crossing the blood-brain barrier with nanoparticles. J Control Release  2018,270,290-303","journal-title":"J Control Release"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/sj.embor.7400439","volume":"6","author":"Hunter P.","year":"2005","unstructured":"Hunter P.; Common defences. EMBO Rep  2005,6(6),504-7","journal-title":"EMBO Rep"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41392-021-00687-0","volume":"6","author":"Li D.","year":"2021","unstructured":"Li D.; Wu M.; Pattern recognition receptors in health and diseases. Signal Transduct Target Ther  2021,6(1),291","journal-title":"Signal Transduct Target Ther"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"Kawai T.","year":"2010","unstructured":"Kawai T.; Akira S.; The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol  2010,11(5),373-84","journal-title":"Nat Immunol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nri.2016.58","volume":"16","author":"Broz P.","year":"2016","unstructured":"Broz P.; Dixit V.M.; Inflammasomes: Mechanism of assembly, regulation and signalling. Nat Rev Immunol  2016,16(7),407-20","journal-title":"Nat Rev Immunol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jmb.2017.11.013","volume":"430","author":"Gaidt M.M.","year":"2018","unstructured":"Gaidt M.M.; Hornung V.; The NLRP3 Inflammasome Renders Cell Death Pro-inflammatory. J Mol Biol  2018,430(2),133-141","journal-title":"J Mol Biol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"Swanson K.V.","year":"2019","unstructured":"Swanson K.V.; Deng M.; Ting J.P.Y.; The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nat Rev Immunol  2019,19(8),477-89","journal-title":"Nat Rev Immunol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.3389\/fimmu.2019.02538","volume":"10","author":"Zahid A.","year":"2019","unstructured":"Zahid A.; Li B.; Kombe A.J.K.; Jin T.; Tao J.; Pharmacological inhibitors of the NLRP3 inflammasome. Front Immunol  2019,10,2538","journal-title":"Front Immunol"},{"key":"ref=21","first-page":"4063562","volume":"2020","author":"Wang Z.","year":"2020","unstructured":"Wang Z.; Zhang S.; Xiao Y.; NLRP3 inflammasome and inflammatory diseases. Oxid Med Cell Longev  2020,2020(1),4063562","journal-title":"Oxid Med Cell Longev"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3390\/ijms22020872","volume":"22","author":"Sharma M.","year":"2021","unstructured":"Sharma M.; de Alba E.; Structure, activation and regulation of NLRP3 and AIM2 inflammasomes. Int J Mol Sci  2021,22(2),872","journal-title":"Int J Mol Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/j.jaci.2021.04.018","volume":"147","author":"Wang L.","year":"2021","unstructured":"Wang L.; Sharif H.; Vora S.M.; Zheng Y.; Wu H.; Structures and functions of the inflammasome engine. J Allergy Clin Immunol  2021,147(6),2021-9","journal-title":"J Allergy Clin Immunol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","volume":"140","author":"Schroder K.","year":"2010","unstructured":"Schroder K.; Tschopp J.; The inflammasomes. Cell  2010,140(6),821-32","journal-title":"Cell"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41586-019-1295-z","volume":"570","author":"Sharif H.","year":"2019","unstructured":"Sharif H.; Wang L.; Wang W.L.; Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome. Nature  2019,570(7761),338-43","journal-title":"Nature"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.3390\/ijms23031651","volume":"23","author":"Moasses G.S.","year":"2022","unstructured":"Moasses G.S.; Soriano-Teruel P.M.; Lotfollahzadeh S.; Identification of NLRP3PYD homo-oligomerization inhibitors with anti-inflammatory activity. Int J Mol Sci  2022,23(3),1651","journal-title":"Int J Mol Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41467-017-00227-x","volume":"8","author":"Tang T.","year":"2017","unstructured":"Tang T.; Lang X.; Xu C.; CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation. Nat Commun  2017,8(1),202","journal-title":"Nat Commun"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.immuni.2013.05.016","volume":"38","author":"Mu\u00f1oz-Planillo R.","year":"2013","unstructured":"Mu\u00f1oz-Planillo R.; Kuffa P.; Mart\u00ednez-Col\u00f3n G.; Smith B.L.; Rajendiran T.M.; N\u00fa\u00f1ez G.; K\u207a efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity  2013,38(6),1142-53","journal-title":"Immunity"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"8384","DOI":"10.1074\/jbc.RA118.006508","volume":"294","author":"Yu S.","unstructured":"Yu S.; Wang D.; Huang L.; The complement receptor C5aR2 promotes protein kinase R expression and contributes to NLRP3 inflammasome activation and HMGB1 release from macrophages. J Biol Chem 2019  ,294(21),8384-94","journal-title":"J Biol Chem 2019"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.4049\/jimmunol.1300489","volume":"191","author":"Laudisi F.","year":"2013","unstructured":"Laudisi F.; Spreafico R.; Evrard M.; Cutting edge: The NLRP3 inflammasome links complement-mediated inflammation and IL-1\u03b2 release. J Immunol  2013,191(3),1006-1010","journal-title":"J Immunol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3389\/fmed.2020.00506","volume":"7","author":"Gratal P.","year":"2020","unstructured":"Gratal P.; Lamuedra A.; Medina J.P.; Purinergic system signaling in metainflammation-associated osteoarthritis. Front Med  2020,7,506","journal-title":"Front Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/imr.12909","volume":"297","author":"Zheng M.","year":"2020","unstructured":"Zheng M.; Kanneganti T.D.; The regulation of the ZBP1\u2010NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis). Immunol Rev  2020,297(1),26-38","journal-title":"Immunol Rev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"E961","DOI":"10.1073\/pnas.1613305114","volume":"114","author":"Conos S.A.","year":"2017","unstructured":"Conos S.A.; Chen K.W.; De Nardo D.; Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner. Proc Natl Acad Sci USA  2017,114(6),E961-E969","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.3390\/cells9081812","volume":"9","author":"Menini S.","year":"2020","unstructured":"Menini S.; Iacobini C.; Vitale M.; Pugliese G.; The inflammasome in chronic complications of diabetes and related metabolic disorders. Cells  2020,9(8),1812","journal-title":"Cells"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fneur.2018.00135","volume":"9","author":"Keane RW","year":"2018","unstructured":"Keane RW; Dietrich WD; de Rivero VJP; Inflammasome proteins as biomarkers of multiple sclerosis. Front Neurol  2018,9,135","journal-title":"Front Neurol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1007\/s12035-023-03618-y","volume":"61","author":"Hou B.","year":"2024","unstructured":"Hou B.; Yin J.; Liu S.; Inhibiting the NLRP3 inflammasome with MCC950 alleviates neurological impairment in the brain of EAE mice. Mol Neurobiol  2024,61(3),1318-30","journal-title":"Mol Neurobiol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/cns.12758","volume":"23","author":"Ke P.","year":"2017","unstructured":"Ke P.; Shao B.Z.; Xu Z.Q.; Chen X.W.; Wei W.; Liu C.; Activating \u03b17 nicotinic acetylcholine receptor inhibits NLRP 3 inflammasome through regulation of \u03b2\u2010arrestin\u20101. CNS Neurosci Ther  2017,23(11),875-884","journal-title":"CNS Neurosci Ther"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"10480","DOI":"10.1073\/pnas.1201836109","volume":"109","author":"Inoue M.","year":"2012","unstructured":"Inoue M.; Williams K.L.; Gunn M.D.; Shinohara M.L.; NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA  2012,109(26),10480-5","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/cei\/uxab023","volume":"207","author":"Yu X.","year":"2022","unstructured":"Yu X.; Lv J.; Wu J.; Chen Y.; Chen F.; Wang L.; The autoimmune encephalitis-related cytokine TSLP in the brain primes neuroinflammation by activating the JAK2-NLRP3 axis. Clin Exp Immunol  2022,207(1),113-22","journal-title":"Clin Exp Immunol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1172\/JCI121901","volume":"128","author":"Zhang C.J.","year":"2018","unstructured":"Zhang C.J.; Jiang M.; Zhou H.; TLR-stimulated IRAKM activates caspase-8 inflammasome in microglia and promotes neuroinflammation. J Clin Invest  2018,128(12),5399-412","journal-title":"J Clin Invest"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1016\/j.bbrc.2018.07.143","volume":"503","author":"Bai X.Y.","year":"2018","unstructured":"Bai X.Y.; Wang X.F.; Zhang L.S.; Du P.C.; Cao Z.; Hou Y.; Tetramethylpyrazine ameliorates experimental autoimmune encephalomyelitis by modulating the inflammatory response. Biochem Biophys Res Commun  2018,503(3),1968-72","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0002-9440(10)64436-7","volume":"161","author":"Ahmed Z.","year":"2002","unstructured":"Ahmed Z.; Doward A.I.; Pryce G.; A role for caspase-1 and -3 in the pathology of experimental allergic encephalomyelitis : Inflammation versus degeneration. Am J Pathol  2002,161(5),1577-86","journal-title":"Am J Pathol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.4049\/jimmunol.1000217","volume":"184","author":"Shaw P.J.","year":"2010","unstructured":"Shaw P.J.; Lukens J.R.; Burns S.; Chi H.; McGargill M.A.; Kanneganti T.D.; Cutting edge: Critical role for PYCARD\/ASC in the development of experimental autoimmune encephalomyelitis. J Immunol  2010,184(9),4610-4614","journal-title":"J Immunol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"3000529","DOI":"10.1371\/journal.pbio.3000529","volume":"17","author":"Walle L.V.","year":"2019","unstructured":"Walle L.V.; Stowe I.B.; \u0160\u00e1cha P.; Correction: MCC950\/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition. PLoS Biol  2019,17(10),3000529","journal-title":"PLoS Biol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","volume":"21","author":"Coll R.C.","year":"2015","unstructured":"Coll R.C.; Robertson A.A.B.; Chae J.J.; A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med  2015,21(3),248-55","journal-title":"Nat Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10787-017-0401-9","volume":"26","author":"Khan N.","year":"2018","unstructured":"Khan N.; Kuo A.; Brockman D.A.; Cooper M.A.; Smith M.T.; Pharmacological inhibition of the NLRP3 inflammasome as a potential target for multiple sclerosis induced central neuropathic pain. Inflammopharmacology  2018,26(1),77-86","journal-title":"Inflammopharmacology"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12974-020-01778-5","volume":"17","author":"O\u2019Brien W.T.","year":"2020","unstructured":"O\u2019Brien W.T.; Pham L.; Symons G.F.; Monif M.; Shultz S.R.; McDonald S.J.; The NLRP3 inflammasome in traumatic brain injury: Potential as a biomarker and therapeutic target. J Neuroinflammation  2020,17(1),104","journal-title":"J Neuroinflammation"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"eaah4066","DOI":"10.1126\/scitranslmed.aah4066","volume":"10","author":"Gordon R.","year":"2018","unstructured":"Gordon R.; Albornoz E.A.; Christie D.C.; Inflammasome inhibition prevents \u03b1-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med  2018,10(465),eaah4066","journal-title":"Sci Transl Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.bbi.2016.12.014","volume":"61","author":"Dempsey C.","year":"2017","unstructured":"Dempsey C.; Rubio A.A.; Bryson K.J.; Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-\u03b2 and cognitive function in APP\/PS1 mice. Brain Behav Immun  2017,61,306-316","journal-title":"Brain Behav Immun"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1021\/acschembio.1c00218","volume":"16","author":"Kennedy C.R.","year":"2021","unstructured":"Kennedy C.R.; Goya G.A.; Kova\u010di\u010d T.; A probe for NLRP3 inflammasome inhibitor MCC950 identifies carbonic anhydrase 2 as a novel target. ACS Chem Biol  2021,16(6),982-990","journal-title":"ACS Chem Biol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","volume":"15","author":"Coll R.C.","year":"2019","unstructured":"Coll R.C.; Hill J.R.; Day C.J.; MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat Chem Biol  2019,15(6),556-9","journal-title":"Nat Chem Biol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41589-019-0278-6","volume":"15","author":"Tapia-Abell\u00e1n A.","year":"2019","unstructured":"Tapia-Abell\u00e1n A.; Angosto-Bazarra D.; Mart\u00ednez-Banaclocha H.; MCC950 closes the active conformation of NLRP3 to an inactive state. Nat Chem Biol  2019,15(6),560-4","journal-title":"Nat Chem Biol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"12077","DOI":"10.1074\/jbc.M117.797126","volume":"292","author":"Domingo-Fern\u00e1ndez R.","year":"2017","unstructured":"Domingo-Fern\u00e1ndez R.; Coll R.C.; Kearney J.; Breit S.; O\u2019Neill L.A.J.; The intracellular chloride channel proteins CLIC1 and CLIC4 induce IL-1\u03b2 transcription and activate the NLRP3 inflammasome. J Biol Chem  2017,292(29),12077-87","journal-title":"J Biol Chem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1089\/neu.2017.5344","volume":"35","author":"Ismael S.","year":"2018","unstructured":"Ismael S.; Nasoohi S.; Ishrat T.; MCC950, the selective inhibitor of nucleotide oligomerization domain-like receptor protein-3 inflammasome, protects mice against traumatic brain injury. J Neurotrauma  2018,35(11),1294-303","journal-title":"J Neurotrauma"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fmolb.2020.00037","volume":"7","author":"Jiao J.","year":"2020","unstructured":"Jiao J.; Zhao G.; Wang Y.; Ren P.; Wu M.; MCC950, a selective inhibitor of NLRP3 inflammasome, reduces the inflammatory response and improves neurological outcomes in mice model of spinal cord injury. Front Mol Biosci  2020,7,37","journal-title":"Front Mol Biosci"},{"key":"ref=56","first-page":"5","volume":"17","author":"Mart\u00ednez-God\u00ednez M.A.","year":"2015","unstructured":"Mart\u00ednez-God\u00ednez M.A.; Cruz-Dom\u00ednguez M.P.; Jara L.J.; Expression of NLRP3 inflammasome, cytokines and vascular mediators in the skin of systemic sclerosis patients. Isr Med Assoc J  2015,17(1),5-10","journal-title":"Isr Med Assoc J"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1136\/annrheumdis-2013-203276","volume":"73","author":"Mathews R.J.","year":"2014","unstructured":"Mathews R.J.; Robinson J.I.; Battellino M.; Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis  2014,73(6),1202-1210","journal-title":"Ann Rheum Dis"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"12877","DOI":"10.21037\/apm-21-3472","volume":"10","author":"Zhuang Y.","year":"2021","unstructured":"Zhuang Y.; Wang H.; Su J.; A narrative review of positive regulation of NLRP3 inflammasome in rheumatoid arthritis. Ann Palliat Med  2021,10(12),12877-85","journal-title":"Ann Palliat Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1093\/rheumatology\/keac273","volume":"61","author":"Weber A.N.R.","year":"2022","unstructured":"Weber A.N.R.; Tapia-Abell\u00e1n A.; Liu X.; Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950\/CRID3. Rheumatology  2022,61(10),e299-313","journal-title":"Rheumatology"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jdermsci.2022.12.006","volume":"108","author":"Liu C.","year":"2022","unstructured":"Liu C.; Tang J.; Liu S.; Cathepsin B\/NLRP3\/GSDMD axis-mediated macrophage pyroptosis induces inflammation and fibrosis in systemic sclerosis. J Dermatol Sci  2022,108(3),127-37","journal-title":"J Dermatol Sci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00204-019-02411-y","volume":"93","author":"Hindman B.","year":"2019","unstructured":"Hindman B.; Ma Q.; Carbon nanotubes and crystalline silica stimulate robust ROS production, inflammasome activation, and IL-1\u03b2 secretion in macrophages to induce myofibroblast transformation. Arch Toxicol  2019,93(4),887-907","journal-title":"Arch Toxicol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"R33","DOI":"10.1186\/ar4184","volume":"15","author":"Caorsi R.","year":"2013","unstructured":"Caorsi R.; Lepore L.; Zulian F.; The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res Ther  2013,15(1),R33","journal-title":"Arthritis Res Ther"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/rheumatology\/kev416","volume":"55","author":"Kuemmerle-Deschner J.B.","year":"2016","unstructured":"Kuemmerle-Deschner J.B.; Hofer F.; Endres T.; Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. Rheumatology  2016,55(4),689-96","journal-title":"Rheumatology"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"175091","DOI":"10.1016\/j.ejphar.2022.175091","volume":"928","author":"Li H.","year":"2022","unstructured":"Li H.; Guan Y.; Liang B.; Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome. Eur J Pharmacol  2022,928,175091","journal-title":"Eur J Pharmacol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/nan.12621","volume":"46","author":"Yue J.","year":"2020","unstructured":"Yue J.; Wei Y.J.; Yang X.L.; Liu S.Y.; Yang H.; Zhang C.Q.; NLRP3 inflammasome and endoplasmic reticulum stress in the epileptogenic zone in temporal lobe epilepsy: Molecular insights into their interdependence. Neuropathol Appl Neurobiol  2020,46(7),770-85","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1016\/j.celrep.2018.02.027","volume":"22","author":"Cohen T.S.","year":"2018","unstructured":"Cohen T.S.; Boland M.L.; Boland B.B.; S. aureus evades macrophage killing through NLRP3-dependent effects on mitochondrial trafficking. Cell Rep  2018,22(9),2431-41","journal-title":"Cell Rep"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"27912","DOI":"10.1038\/srep27912","volume":"6","author":"Tate M.D.","year":"2016","unstructured":"Tate M.D.; Ong J.D.H.; Dowling J.K.; Reassessing the role of the NLRP3 inflammasome during pathogenic influenza A virus infection via temporal inhibition. Sci Rep  2016,6(1),27912","journal-title":"Sci Rep"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"8618","DOI":"10.1038\/s41598-018-26775-w","volume":"8","author":"Perera AP","year":"2018","unstructured":"Perera AP; Fernando R; Shinde T; MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice. Sci Rep  2018,8(1),8618","journal-title":"Sci Rep"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/nature16959","volume":"530","author":"He Y.","year":"2016","unstructured":"He Y.; Zeng M.Y.; Yang D.; Motro B.; N\u00fa\u00f1ez G.; NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature  2016,530(7590),354-7","journal-title":"Nature"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3390\/antiox9080647","volume":"9","author":"Picca A.","year":"2020","unstructured":"Picca A.; Calvani R.; Coelho-Junior H.J.; Landi F.; Bernabei R.; Marzetti E.; Mitochondrial dysfunction, oxidative stress, and neuroinflammation: Intertwined roads to neurodegeneration. Antioxidants  2020,9(8),647","journal-title":"Antioxidants"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1080\/15548627.2015.1121361","volume":"12","author":"Kang C.","year":"2016","unstructured":"Kang C.; Elledge S.J.; How autophagy both activates and inhibits cellular senescence. Autophagy  2016,12(5),898-899","journal-title":"Autophagy"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/brain\/awl075","volume":"129","author":"Gold R.","year":"2006","unstructured":"Gold R.; Linington C.; Lassmann H.; Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain  2006,129(8),1953-71","journal-title":"Brain"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/j.1471-4159.2010.06982.x","volume":"115","author":"Farooqi N.","year":"2010","unstructured":"Farooqi N.; Gran B.; Constantinescu C.S.; Are current disease\u2010modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis? J Neurochem  2010,115(4),829-44","journal-title":"J Neurochem"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","volume":"164","author":"Constantinescu C.S.","year":"2011","unstructured":"Constantinescu C.S.; Farooqi N.; O\u2019Brien K.; Gran B.; Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol  2011,164(4),1079-1106","journal-title":"Br J Pharmacol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/B978-0-444-52001-2.00008-X","volume":"122","author":"Robinson A.P.","year":"2014","unstructured":"Robinson A.P.; Harp C.T.; Noronha A.; Miller S.D.; The experimental autoimmune encephalomyelitis (EAE) model of MS. Handb Clin Neurol  2014,122,173-89","journal-title":"Handb Clin Neurol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41419-020-2565-2","volume":"11","author":"Hou B.","year":"2020","unstructured":"Hou B.; Zhang Y.; Liang P.; Inhibition of the NLRP3-inflammasome prevents cognitive deficits in experimental autoimmune encephalomyelitis mice via the alteration of astrocyte phenotype. Cell Death Dis  2020,11(5),377","journal-title":"Cell Death Dis"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.molimm.2019.09.020","volume":"116","author":"Zhang J.","year":"2019","unstructured":"Zhang J.; Zheng Y.; Luo Y.; Du Y.; Zhang X.; Fu J.; Curcumin inhibits LPS-induced neuroinflammation by promoting microglial M2 polarization via TREM2\/ TLR4\/ NF-\u03baB pathways in BV2 cells. Mol Immunol  2019,116,29-37","journal-title":"Mol Immunol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/jnc.15650","volume":"163","author":"Galloway D.A.","year":"2022","unstructured":"Galloway D.A.; Carew S.J.; Blandford S.N.; Investigating the NLRP3 inflammasome and its regulator miR \u2010223\u20103p in multiple sclerosis and experimental demyelination. J Neurochem  2022,163(2),94-112","journal-title":"J Neurochem"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2174\/1570159X23666241206102022","volume":"23","author":"Kalaki-Jouybari F.","year":"2025","unstructured":"Kalaki-Jouybari F.; Shirzad M.; Javan M.; Ghasemi-Kasman M.; Pouramir M.; Co-administration of Naringin and NLRP3 inhibitor improves myelin repair and mitigates oxidative stress in cuprizone-induced demyelination model. Curr Neuropharmacol  2025,23(4),475-91","journal-title":"Curr Neuropharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"177851","DOI":"10.1016\/j.ejphar.2025.177851","volume":"1002","author":"Askari H.","year":"2025","unstructured":"Askari H.; Yavarpour-Bali H.; Shirzad M.; Sadeghi F.; Biagini G.; Ghasemi-Kasman M.; Combination therapy with exosomes and NLRP3 inhibition enhances myelin repair in a cuprizone-induced demyelination model. Eur J Pharmacol  2025,1002,177851","journal-title":"Eur J Pharmacol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.1002\/jcb.27792","volume":"120","author":"Xu L.","year":"2019","unstructured":"Xu L.; Zhang C.; Jiang N.; He D.; Bai Y.; Xin Y.; Rapamycin combined with MCC950 to treat multiple sclerosis in experimental autoimmune encephalomyelitis. J Cell Biochem  2019,120(4),5160-5168","journal-title":"J Cell Biochem"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"117747","DOI":"10.1016\/j.lfs.2020.117747","volume":"253","author":"Xu L.","year":"2020","unstructured":"Xu L.; Zhang C.; He D.; Jiang N.; Bai Y.; Xin Y.; Rapamycin and MCC950 modified gut microbiota in experimental autoimmune encephalomyelitis mouse by brain gut axis. Life Sci  2020,253,117747","journal-title":"Life Sci"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.3390\/pharmaceutics15112599","volume":"15","author":"Niazi S.K.","year":"2023","unstructured":"Niazi S.K.; Non-invasive drug delivery across the blood\u2013brain barrier: A prospective analysis. Pharmaceutics  2023,15(11),2599","journal-title":"Pharmaceutics"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1124\/pharmrev.122.000629","volume":"75","author":"Ma Q.","year":"2023","unstructured":"Ma Q.; Pharmacological inhibition of the NLRP3 inflammasome: Structure, molecular activation, and inhibitor-NLRP3 interaction. Pharmacol Rev  2023,75(3),487-520","journal-title":"Pharmacol Rev"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.tips.2025.04.007","volume":"46","author":"Cabral J.E.","year":"2025","unstructured":"Cabral J.E.; Wu A.; Zhou H.; Pham M.A.; Lin S.; McNulty R.; Targeting the NLRP3 inflammasome for inflammatory disease therapy. Trends Pharmacol Sci  2025,46(6),503-519","journal-title":"Trends Pharmacol Sci"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1515\/tnsci-2022-0258","volume":"13","author":"Mittal K.R.","year":"2022","unstructured":"Mittal K.R.; Pharasi N.; Sarna B.; Nanotechnology-based drug delivery for the treatment of CNS disorders. Transl Neurosci  2022,13(1),527-46","journal-title":"Transl Neurosci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"33322","DOI":"10.1021\/acsami.3c04206","volume":"15","author":"Negro R.","year":"2023","unstructured":"Negro R.; Mastrogiacomo R.; Carrieri L.; Encapsulation of MCC950 in liposomes decorated with anti-frizzled 1 improves drug bioavailability and effectiveness in fatty liver disease. ACS Appl Mater Interfaces  2023,15(28),33322-33334","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1021\/acschemneuro.4c00024","volume":"15","author":"Sharma S.","year":"2024","unstructured":"Sharma S.; Risen S.; Gilberto V.S.; Targeted-Neuroinflammation Mitigation Using Inflammasome-Inhibiting Nanoligomers is Therapeutic in an Experimental Autoimmune Encephalomyelitis Mouse Model. ACS Chem Neurosci  2024,15(7),1596-608","journal-title":"ACS Chem Neurosci"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.chom.2009.05.002","volume":"5","author":"Hise A.G.","year":"2009","unstructured":"Hise A.G.; Tomalka J.; Ganesan S.; An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans. Cell Host Microbe  2009,5(5),487-97","journal-title":"Cell Host Microbe"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"107506","DOI":"10.1016\/j.intimp.2021.107506","volume":"97","author":"Wang X.","year":"2021","unstructured":"Wang X.; Chen S.; Zhao L.; Shi X.; Protective effect of combination of anakinra and MCC950 against acute lung injury is achieved through suppression of the NF-\u03baB-mediated-MAPK and NLRP3-caspase pathways. Int Immunopharmacol  2021,97,107506","journal-title":"Int Immunopharmacol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"019177","DOI":"10.1161\/JAHA.120.019177","volume":"10","author":"Liang L.","year":"2021","unstructured":"Liang L.; Zhang G.; Li H.; Combined therapy with polyethylene glycol\u201020k and mcc950 preserves post\u2010resuscitated myocardial function in a rat model of cardiac arrest and cardiopulmonary resuscitation. J Am Heart Assoc  2021,10(9),019177","journal-title":"J Am Heart Assoc"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.brainres.2019.01.005","volume":"1710","author":"Chen Y.","year":"2019","unstructured":"Chen Y.; Meng J.; Xu Q.; Rapamycin improves the neuroprotection effect of inhibition of NLRP3 inflammasome activation after TBI. Brain Res  2019,1710,163-72","journal-title":"Brain Res"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10787-020-00730-6","volume":"29","author":"Saber S.","year":"2021","unstructured":"Saber S.; El-Kader E.M.A.; Novel complementary coloprotective effects of metformin and MCC950 by modulating HSP90\/NLRP3 interaction and inducing autophagy in rats. Inflammopharmacology  2021,29(1),237-51","journal-title":"Inflammopharmacology"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1038\/s41598-020-60560-y","volume":"10","author":"Subbarao S.","year":"2020","unstructured":"Subbarao S.; Sanchez-Garrido J.; Krishnan N.; Shenoy A.R.; Robertson B.D.; Genetic and pharmacological inhibition of inflammasomes reduces the survival of Mycobacterium tuberculosis strains in macrophages. Sci Rep  2020,10(1),3709","journal-title":"Sci Rep"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3390\/molecules29030712","volume":"29","author":"Yan X.","year":"2024","unstructured":"Yan X.; Fu P.; Zhang Y.; MCC950 ameliorates diabetic muscle atrophy in mice by inhibition of pyroptosis and its synergistic effect with aerobic exercise. Molecules  2024,29(3),712","journal-title":"Molecules"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"70092","DOI":"10.1002\/hem3.70092","volume":"9","author":"Starobova H.","year":"2025","unstructured":"Starobova H.; McCalmont H.; Shatunova S.; Inhibition of the NLRP3 inflammasome using MCC950 reduces vincristine\u2010induced adverse effects in an acute lymphoblastic leukemia patient\u2010derived xenograft model. HemaSphere  2025,9(3),70092","journal-title":"HemaSphere"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"40817","DOI":"10.18632\/oncotarget.17256","volume":"8","author":"Ko J.H.","year":"2017","unstructured":"Ko J.H.; Yoon S.O.; Lee H.J.; Oh J.Y.; Rapamycin regulates macrophage activation by inhibiting NLRP3 inflammasome-p38 MAPK-NF\u03baB pathways in autophagy- and p62-dependent manners. Oncotarget  2017,8(25),40817-31","journal-title":"Oncotarget"}],"container-title":["Current Reviews in Clinical and Experimental Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724328444835260407154423","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/253796\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724328444835260407154423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:41:17Z","timestamp":1790145677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/253796\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":97,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0127724328444835260407154423","relation":{},"ISSN":["2772-4328"],"issn-type":[{"value":"2772-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-10-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}